If you or a loved one is taking Tysabri, you may have heard about the risk of progressive multifocal leukoencephalopathy (PML) and wonder what it means. Decades of research on immune-modulating therapies have established that any drug affecting the immune system carries some risk of opportunistic infections. This page explains how doctors frame the PML risk for Tysabri patients and what monitoring protocols are recommended.
Tysabri (natalizumab) is a monoclonal antibody used as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. The drug's prescribing information contains a boxed warning stating that Tysabri increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain caused by the JC virus (JCV) that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This warning is based on clinical trial data and postmarketing surveillance that have established a causal link between Tysabri exposure and PML development. The clinical presentation of PML includes progressive neurological deficits such as weakness, cognitive impairment, visual disturbances, and coordination problems. Diagnosis typically requires brain MRI showing characteristic white matter lesions and detection of JCV DNA in cerebrospinal fluid via polymerase chain reaction. In Tysabri-treated patients, PML can occur without overt immunosuppression, as the drug's mechanism of action—blocking alpha-4 integrin-mediated lymphocyte trafficking to the brain—impairs immune surveillance against JCV (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This mechanistic pathway explains why Tysabri, unlike other immunosuppressants, creates a specific vulnerability to JCV reactivation in the central nervous system.
Three established risk factors for PML in Tysabri-treated patients have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Anti-JCV antibody positivity indicates prior exposure to JCV and increases baseline risk. Treatment duration beyond two years further elevates risk, likely due to prolonged impairment of immune surveillance. Prior immunosuppressant use may compound this risk by further compromising immune function. These factors should be considered in the context of expected benefit when initiating and continuing treatment with Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The timeline between Tysabri exposure and documented harm varies. In clinical trials, PML occurred in three patients: two with multiple sclerosis who had received Tysabri for a median of 120 weeks in addition to interferon beta-1a, and one with Crohn's disease after eight doses (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Postmarketing data have shown PML can occur as early as a few months after starting Tysabri, though risk increases with cumulative exposure. The prescribing information advises healthcare professionals to monitor patients for any new sign or symptom suggestive of PML and to withhold Tysabri immediately at the first sign or symptom (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Adequacy of warnings regarding Tysabri and PML is addressed through the boxed warning, which is the strongest safety communication required by the FDA. The warning explicitly states that Tysabri increases PML risk and lists known risk factors. Additionally, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program, which mandates education, monitoring, and reporting requirements (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This program aims to ensure that patients and healthcare providers are aware of PML risk and that early detection and management are prioritized. For affected patients, causation-related considerations include the strength of the association between Tysabri and PML, which is supported by clinical trial evidence, biological plausibility, and consistent postmarketing reports. The drug's labeling acknowledges that PML usually leads to death or severe disability, underscoring the seriousness of this adverse effect (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who develop PML while on Tysabri may have legal and medical recourse, but the primary focus remains on risk mitigation through careful patient selection, monitoring, and prompt discontinuation of therapy if PML is suspected. In summary, the evidence demonstrates that Tysabri causes PML through a well-understood mechanistic pathway involving impaired immune surveillance against JCV. The risk is modulated by identifiable factors, and the drug's labeling provides clear warnings and monitoring recommendations. The timeline from exposure to harm can range from months to years, with risk increasing over time. These findings underscore the importance of balancing therapeutic benefit against PML risk in clinical decision-making.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Tysabri (natalizumab) has been shown to increase the risk of progressive multifocal leukoencephalopathy (PML), a serious brain infection caused by the JC virus. The drug's boxed warning and clinical data establish a causal link, as Tysabri impairs immune surveillance in the central nervous system, allowing JCV to reactivate and cause PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Three main risk factors have been identified: presence of anti-JCV antibodies, longer treatment duration (especially over two years), and prior use of immunosuppressants. These factors increase the likelihood of PML and should be considered when initiating and continuing Tysabri therapy (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
PML can occur as early as a few months after starting Tysabri, but the risk increases with cumulative exposure. In clinical trials, PML occurred after a median of 120 weeks in multiple sclerosis patients and after eight doses in a Crohn's disease patient. Postmarketing data confirm that risk rises with longer treatment duration (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.